Akhtar Muzamil, Nashwan Abdulqadir J
College of Medicine, Gujranwala Medical College, Gujranwala 52250, Punjab, Pakistan.
Department of Nursing and Midwifery Research, Hamad Medical Corporation, Doha 3050, Qatar.
World J Methodol. 2025 Jun 20;15(2):100074. doi: 10.5662/wjm.v15.i2.100074.
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder affecting over 2% of the global population, marked by social communication deficits and repetitive behaviors. Kabatas explored the efficacy and safety of Wharton's jelly-derived mesenchymal stem cell (WJ-MSC) therapy in a 4-year-old child with ASD. Using the childhood autism rating scale and Denver II developmental screening test, significant improvements were seen after six WJ-MSC sessions, with no adverse events over 2 years. Despite promising results, the study's single-case design limits generalizability. Larger, multi-center trials are needed to validate the findings and assess long-term effects of WJ-MSC therapy in ASD.
自闭症谱系障碍（ASD）是一种复杂的神经发育障碍，影响着全球超过2%的人口，其特征是社交沟通缺陷和重复行为。卡巴塔斯研究了源自沃顿胶的间充质干细胞（WJ-MSC）疗法对一名4岁自闭症谱系障碍患儿的疗效和安全性。使用儿童自闭症评定量表和丹佛发育筛查测验第二版，在进行六次WJ-MSC治疗后有显著改善，且在两年内无不良事件。尽管结果令人鼓舞，但该研究的单病例设计限制了可推广性。需要开展更大规模的多中心试验来验证这些发现，并评估WJ-MSC疗法对自闭症谱系障碍的长期影响。
